Scholarlink

Background <p>While neoadjuvant chemoradiation (NCRT) has been the acceptable standard of care for esophageal adenocarcinoma (EAC), there has been a paradigm shift based&#xa0;on recent trials showing neoadjuvant chemotherapy (NCT) as being either equivalent or superior to NCRT. We sought to examine the outcomes of NCT versus NCRT in esophageal cancer.</p> Methods <p>Utilizing the National Cancer Database, we identified esophagectomy patients with EAC who underwent multi-agent NCT versus multi-agent NCRT. Groups were statistically equated with propensity score-matched (PSM) analysis.</p> Results <p>After PSM, we identified 1007 patients in each group. There was improved lymphadenectomy and higher use of adjuvant therapy in the NCT group, and significant improvements in R0 resection and pathologic response associated with NCRT. There was also a significant improvement in overall survival (OS) in the NCT versus NCRT groups. The median and 5-year OS were 42.7 months and 42% in NCT versus 34.2 months and 35% in NCRT (<i>p</i>&#xa0;=&#xa0;0.001). For pathologic complete responders, median and 5-year OS were 101 months and 64% in NCT versus 71.2 months and 53% in NCRT (<i>p</i>&#xa0;=&#xa0;0.04). On multivariate analysis, reduced mortality was associated with female sex, pathologic N0, &gt;10 nodes removed, pathologic partial or complete response, R0, well/moderate grade, NCT, adjuvant chemotherapy, and higher facility volume.</p> Conclusions <p>Despite the higher R0 rate and pathologic response associated with NCRT, NCT was associated with improved OS compared with NCRT in EAC patients. While NCT shows an OS advantage in this dataset, regimen heterogeneity precludes definitive therapeutic recommendations.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Outcomes of Neoadjuvant Chemotherapy Versus Chemoradiation for Esophageal Adenocarcinoma: A National Cancer Database Analysis

  • 期刊论文

  • 发表日期：

    2025年8月23日

查看全文
  • Ravi Shridhar,
  • Jamie Huston,
  • Kenneth Meredith

摘要

Background

While neoadjuvant chemoradiation (NCRT) has been the acceptable standard of care for esophageal adenocarcinoma (EAC), there has been a paradigm shift based on recent trials showing neoadjuvant chemotherapy (NCT) as being either equivalent or superior to NCRT. We sought to examine the outcomes of NCT versus NCRT in esophageal cancer.

Methods

Utilizing the National Cancer Database, we identified esophagectomy patients with EAC who underwent multi-agent NCT versus multi-agent NCRT. Groups were statistically equated with propensity score-matched (PSM) analysis.

Results

After PSM, we identified 1007 patients in each group. There was improved lymphadenectomy and higher use of adjuvant therapy in the NCT group, and significant improvements in R0 resection and pathologic response associated with NCRT. There was also a significant improvement in overall survival (OS) in the NCT versus NCRT groups. The median and 5-year OS were 42.7 months and 42% in NCT versus 34.2 months and 35% in NCRT (p = 0.001). For pathologic complete responders, median and 5-year OS were 101 months and 64% in NCT versus 71.2 months and 53% in NCRT (p = 0.04). On multivariate analysis, reduced mortality was associated with female sex, pathologic N0, >10 nodes removed, pathologic partial or complete response, R0, well/moderate grade, NCT, adjuvant chemotherapy, and higher facility volume.

Conclusions

Despite the higher R0 rate and pathologic response associated with NCRT, NCT was associated with improved OS compared with NCRT in EAC patients. While NCT shows an OS advantage in this dataset, regimen heterogeneity precludes definitive therapeutic recommendations.